Active	Status	Sponsor type	Region	Phase	Filter
6 Active 4 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Woodward, Michael
ATTENTION-AD, NCT04314934: OLE of Phase 2b/3 Study ANAVEX2-73-AD-004	Completed	2/3	300	Europe, Canada, RoW	ANAVEX2-73, Blarcamesine	Anavex Life Sciences Corp., Anavex Australia Pty Ltd., Anavex Germany GmbH	Alzheimer Disease	06/24	06/24
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease	Active, not recruiting	2	367	Europe, Canada, US, RoW	GSK4527226, Placebo	GlaxoSmithKline, Alector Inc.	Alzheimer's Disease	11/26	11/26
Zeimer, Henry
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease	Completed	3	804	Canada, US, RoW	Simufilam, PTI-125, Placebo	Cassava Sciences, Inc., Premier Research Group plc	Alzheimer Disease	10/24	10/24
NCT06114745: A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease	Active, not recruiting	1	12	RoW	SHR-1707 injection, Placebo	Atridia Pty Ltd.	Alzheimer's Disease (AD)	11/25	11/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Woodward, Michael
ATTENTION-AD, NCT04314934: OLE of Phase 2b/3 Study ANAVEX2-73-AD-004	Completed	2/3	300	Europe, Canada, RoW	ANAVEX2-73, Blarcamesine	Anavex Life Sciences Corp., Anavex Australia Pty Ltd., Anavex Germany GmbH	Alzheimer Disease	06/24	06/24
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease	Active, not recruiting	2	367	Europe, Canada, US, RoW	GSK4527226, Placebo	GlaxoSmithKline, Alector Inc.	Alzheimer's Disease	11/26	11/26
Zeimer, Henry
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease	Completed	3	804	Canada, US, RoW	Simufilam, PTI-125, Placebo	Cassava Sciences, Inc., Premier Research Group plc	Alzheimer Disease	10/24	10/24
NCT06114745: A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease	Active, not recruiting	1	12	RoW	SHR-1707 injection, Placebo	Atridia Pty Ltd.	Alzheimer's Disease (AD)	11/25	11/25